The utility of the cystatin C test in diagnosing kidney disease

12. May 2021 | 3 min read

The utility of the cystatin C test in diagnosing kidney disease

Webinar about cystatin C as an alternative to creatinine

In this exciting webinar a multidisciplinary panel of experts examine the clinical utility of the cystatin C test in diagnosing kidney disease. The aim of this discussion was to educate healthcare practitioners on the cystatin C testing option and help them effectively communicate the benefits of the test to their patients.

Content of the webinar:

  • Importance of Estimated GFR - Josef Coresh, MD, PhD Johns Hopkins University
  • The Epidemiological Argument for Cystatin C and Impact of GFR Staging on Medication Eligibility and Dosing - Michael Shlipak, MD, MPH San Francisco VA Health Care System and University of California, San Francisco
  • Clinical Case Examples - Michelle Estrella, MD, MHS San Francisco VA Health Care System and University of California, San Francisco
  • Barriers to widespread use of cystatin C and how to overcome them - Amy Karger, MD, PhD University of Minnesota


The webinar is sponsored by Gentian Diagnostics.

 

The Gentian Cystatin C Immunoassay

The Gentian Cystatin C Immunoassay is an open channel turbidimetric test for quantitative determination of cystatin C in human serum and plasma.

  • FDA510(k) cleared and CE-marked and IVDR certified
  • Developed and manufactured by Gentian
  • Manufactured according to ISO 13485:2016

 

Order here:

For more information or ordering cystatin C, please fill out the form below:

 

 

 

You may also read


Meet Gentian and explore circulating calprotectin at Autoimmunity 2026

May 05, 2026

Meet Gentian and explore circulating calprotectin at Autoimmunity 2026

Discover new insights in inflammation with calprotectin We are excited to announce that Gentian will be..

GCAL® Calprotectin - From insights to impact - April 2026

Apr 21, 2026

GCAL® Calprotectin - From insights to impact - April 2026

Continuing the GCAL® journey: calprotectin's power to assess inflammation The first quarter has brought..